TY - JOUR
T1 - Japanese Dermatological Association Guidelines
T2 - Outlines of guidelines for cutaneous melanoma 2019
AU - Nakamura, Yasuhiro
AU - Asai, Jun
AU - Igaki, Hiroshi
AU - Inozume, Takashi
AU - Namikawa, Kenjiro
AU - Hayashi, Ayato
AU - Fukushima, Satoshi
AU - Fujimura, Taku
AU - Ito, Takamichi
AU - Imafuku, Keisuke
AU - Tanaka, Ryota
AU - Teramoto, Yukiko
AU - Minagawa, Akane
AU - Miyagawa, Takuya
AU - Miyashita, Azusa
AU - Wada, Makoto
AU - Koga, Hiroshi
AU - Sugaya, Makoto
N1 - Funding Information:
We are grateful to Mr Shinichi Abe for his assistance with the systematic published work search. We also would like to thank Dr Ryuichiro Araki, Assistant Professor of Community Health Science Center, Saitama Medical University, and Dr Hiroshi Yokomichi, Associate Professor of Health Sciences, Basic Sciences for Clinical Medicine, University of Yamanashi, for their contribution of statistical support. Preparation of these guidelines was funded by Japanese Dermatological Association. We did not receive any financial support from other organizations or companies.
Funding Information:
We are grateful to Mr Shinichi Abe for his assistance with the systematic published work search. We also would like to thank Dr Ryuichiro Araki, Assistant Professor of Community Health Science Center, Saitama Medical University, and Dr Hiroshi Yokomichi, Associate Professor of Health Sciences, Basic Sciences for Clinical Medicine, University of Yamanashi, for their contribution of statistical support. Preparation of these guidelines was funded by Japanese Dermatological Association. We did not receive any financial support from other organizations or companies.
Funding Information:
T. F. received research funding from Ono Pharmaceutical and Bristol‐Myers Squibb. S. F. and A. Miyashita received scholarship grants from Ono Pharmaceutical and Bristol‐Myers Squibb. K. Imafuku received a scholarship grant from Taiho Pharmaceutical.
Publisher Copyright:
© 2019 Japanese Dermatological Association
PY - 2020/2/1
Y1 - 2020/2/1
N2 - With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular-targeted agents, has drastically changed the nature of treatment for adjuvant and advanced-stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.
AB - With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular-targeted agents, has drastically changed the nature of treatment for adjuvant and advanced-stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.
KW - cutaneous melanoma
KW - grade system
KW - guidelines
KW - immune checkpoint inhibitor
KW - molecular-targeted agent
UR - http://www.scopus.com/inward/record.url?scp=85075930548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075930548&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.15151
DO - 10.1111/1346-8138.15151
M3 - Article
C2 - 31782186
AN - SCOPUS:85075930548
SN - 0385-2407
VL - 47
SP - 89
EP - 103
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 2
ER -